A-29.01, r. 2.1 - Regulation respecting exceptions to the prohibition against paying or reimbursing the price of a medication or supply covered by the basic prescription drug insurance plan

Updated to 1 June 2024

This document has official status.

chapter A-29.01, r. 2.1

Regulation respecting exceptions to the prohibition against paying or reimbursing the price of a medication or supply covered by the basic prescription drug insurance plan

Act respecting prescription drug insurance

(chapter A-29.01, s. 80.2, par. 1).

1. An accredited manufacturer or wholesaler or an intermediary may pay or reimburse to a person covered by the basic prescription drug insurance plan all or part of the price of the following medications:

(1)  those entered on the list drawn up by the Minister under section 60 of the Act respecting prescription drug insurance (chapter A-29.01) for which the lowest price method does not apply;

(2)  those for which a generic or biosimilar version is not entered on the list drawn up by the Minister under section 60 of the Act.

M.O. 2021-014, s. 1.

2. Where a medication that was referred to in section 1 ceases to be referred to in that section, an accredited manufacturer or wholesaler or an intermediary may continue to pay or reimburse to a person covered by the basic prescription drug insurance plan all or part of the price of the medication for a maximum period of 30 days following the beginning of the application of the lowest price method to the medication or the entry of a generic or biosimilar version on the list drawn up by the Minister under section 60 of the Act, as the case may be.

M.O. 2021-014, s. 2.

3. An accredited manufacturer or wholesaler or an intermediary may continue to pay or reimburse to a person covered by the basic prescription drug insurance plan all or part of the price of a medication that is not referred to in section 1 if, before the coming into force of paragraph 1 of section 80.2 of the Act, that person has already received such a payment or reimbursement for that medication.

M.O. 2021-014, s. 3.

4. (Omitted).

M.O. 2021-014, s. 4.

REFERENCES

M.O. 2021-014, 2021 G.O. 2, 1183